Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.
Koeberle, S.C., Romir, J., Fischer, S., Koeberle, A., Schattel, V., Albrecht, W., Grutter, C., Werz, O., Rauh, D., Stehle, T., Laufer, S.A.(2012) Nat Chem Biol 8: 141-143
- PubMed: 22198732 
- DOI: https://doi.org/10.1038/nchembio.761
- Primary Citation of Related Structures:  
3QUE, 3ZYA - PubMed Abstract: 
Until now, a lack of inhibitors with high potency and selectivity in vivo has hampered investigation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway. We describe the design of skepinone-L, which is, to our knowledge, the first ATP-competitive p38 MAPK inhibitor with excellent in vivo efficacy and selectivity. Therefore, skepinone-L is a valuable probe for chemical biology research, and it may foster the development of a unique class of kinase inhibitors.
Organizational Affiliation: 
Institute of Pharmacy, University of Tübingen, Tübingen, Germany.